CEO Share Purchase
CEO James McCullough purchased 3,010 ADS at average price of US$3.01 per ADS on 11 February 2026.
- ADS purchased 3,010
- Average price per ADS US$3.01
- Total consideration US$9,072
- CEO shareholding post-purchase 3,392,596 Ordinary Shares (0.78% of issued share capital)
Select text to share a quote on X · sign in to keep highlights & notes in your RENX notes
LONDON and NEW YORK, 12 February 2026 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine diagnostics company, whose product kidneyintelX.dkd, is the only FDA-approved and Medicare-reimbursed prognostic test to support early-stage risk assessment in chronic diabetic kidney disease, announces that on 11 February 2026 James McCullough, Chief Executive Officer, bought a total of 3,010 American Depositary Shares (ADS) at an average price of US$3.01 per ADS. ADS consist of 50 Ordinary Shares of £0.0025 each.
Following these purchases, James McCullough is interested in 3,392,596 Ordinary Shares1 representing 0.78% of the issued share capital of the Company.
| a) | Name | James McCullough |
|---|---|---|
| 2 | Reason for the notification | |
| a) | Position/status | Chief Executive O fficer |
| b) | Initial notification /Amendment | Initial Notification |
| a) | Name | Renalytix plc |
| b) | LEI | 213800NTOH3FK3WER551 |
| a) | Description of the financial instrument, type of instrument | American Depository Shares (ADS) which consist of 50 Ordinary Shares at £0.0025 each |
| Identification code | GB00BYWL4Y04 | |
| b) | Nature of the transaction | Purchase of Ordinary Shares |
| c) | Price(s) and volume(s) | |
| Price(s) | Volume(s) | |
| $3.74 | 10 | |
| $2.93 | 500 | |
| $3.01 | 500 | |
| $3.05 | 500 | |
| $3.05 | 500 | |
| $3.02 | 500 | |
| $3.01 | 500 | |
| d) | Aggregated information | |
| - Aggregated volume | 3,010 | |
| - Price | $9,072 | |
| e) | Date of the transaction | 11 February 2026 |
| f) | Place of the transaction | OTC New York |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.